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Abstract
Purpose—Huntington disease (HD) is a chronic, debilitating genetic disease that affects 
physical, emotional, cognitive, and social health. Existing patient-reported outcomes (PROs) of 
health-related quality of life (HRQOL) used in HD are neither comprehensive, nor do they 
adequately account for clinically meaningful changes in function. While new PROs examining 
HRQOL (i.e., Neuro-QoL—Quality of Life in Neurological Disorders and PROMIS—Patient-
Reported Outcomes Measurement Information System) offer solutions to many of these 
shortcomings, they do not include HD-specific content, nor have they been validated in HD. 
HDQLIFE addresses this by validating 12 PROMIS/Neuro-QoL domains in individuals with HD 
and by using established PROMIS methodology to develop new, HD-specific content.
Methods—New item pools were developed using cognitive debriefing with individuals with HD, 
and expert, literacy, and translatability reviews. Existing item banks and new item pools were field 
tested in 536 individuals with prodromal, early-, or late-stage HD.
Results—Moderate to strong relationships between Neuro-QoL/PROMIS measures and generic 
self-report measures of HRQOL, and moderate relationships between Neuro-QoL/PROMIS and 
clinician-rated measures of similar constructs supported the validity of Neuro-QoL/PROMIS in 
individuals with HD. Exploratory and confirmatory factor analysis, item response theory, and 
differential item functioning analyses were utilized to develop new item banks for Chorea, Speech 
Difficulties, Swallowing Difficulties, and Concern with Death and Dying, with corresponding six-
item short forms. A four-item short form was developed for Meaning and Purpose.
Conclusions—HDQLIFE encompasses both validated Neuro-QoL/PROMIS measures, as well 
as five new scales in order to provide a comprehensive assessment of HRQOL in HD.
Keywords
Neuro-QoL; PROMIS; Health-related quality of life; HDQLIFE; Huntington disease; Patient-
reported outcome (PRO)
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Introduction
Huntington disease (HD) is a hereditary neurodegenerative disorder caused by a CAG triplet 
repeat expansion in the gene huntingtin; HD affects approximately 1 in 10,000 individuals in 
populations of European descent [1–4]. Since HD is a dominantly inherited disease, a person 
whose parent carries the HD mutation gene has a 50 % chance inheriting it at the time of 
conception. About 150,000 individuals in the USA are ‘‘at risk’’ for HD. The age of onset of 
HD is inversely related to the length of the CAG repeat; for the most common expansion 
lengths, mutation signs and clinical diagnosis of HD (based on characteristic motor 
symptoms) typically occur between ages 30 and 50. Motor, cognitive, and psychiatric 
abnormalities may emerge gradually, more than a decade before diagnosis (prodromal HD), 
and worsen progressively [5]. Although the rate of clinical progression differs for each 
person, HD is generally fatal within 15–20 years of clinical diagnosis [6]. The fact that this 
progressive, fatal disease typically strikes individuals during the prime of their lives 
underscores the need for interventions that slow the disease progression and maximize 
health-related quality of life (HRQOL).
HRQOL is a multidimensional construct defined as the impact that a disease or disability has 
on different aspects of well-being [7]. This follows the World Health Organization (WHO) 
framework for HRQOL which includes physical, social, and emotional well-being [8]. 
HRQOL differs from general quality of life (QOL), which is a poorly defined concept that 
lacks a consensus definition, that may or may not be synonymous with HRQOL [9, 10]. 
Current measures of HRQOL are insufficient to capture the broad extent of functional and 
symptom distress in HD and are also insensitive to potential intervention effects in HD. 
Most HRQOL measures used in HD were developed for other clinical populations and are 
inadequate because of important differences in symptoms across the neurode-generative 
diseases. For example, although Parkinson’s disease (PD) and HD are both basal ganglia 
disorders characterized by motor abnormalities, these motor manifestations present 
differently; PD is typically characterized by tremor and bradykinesia, whereas HD is 
typically choreic (involuntary ‘‘dance-like’’ movements) and hyperkinetic [11]. Therefore, a 
measure of motor functioning developed for PD may not be meaningful for HD. Similarly, 
although cognitive dysfunction in HD overlaps with cognitive dysfunction in Alzheimer 
disease (AD), individuals with HD typically have ‘‘subcortical’’ deficits (in attention, 
processing speed, and executive dysfunction), whereas individuals with AD also have 
prominent ‘‘cortical’’ deficits (in memory, language, and executive dys-function) [12]. 
Furthermore, generic measures of HRQOL cannot detect subtle differences in function for 
prodromal HD symptoms [13], and single-item ratings [14, 15] have inadequate sensitivity 
and reliability to detect change over time [15]. In addition, the only existing HD-specific 
measure of HRQOL, the HDQoL [16], has evidence to support reliability and construct 
validity, but did not meet minimally established sample size criteria for its developmental 
approach and takes ~22 min to complete [17]. Thus, there is a critical need for a well-
developed, validated, brief HD-specific patient-reported outcome (PRO) measure of 
HRQOL. This is especially important given that the focus of clinical interventions for HD is 
not just to prolong life, but also to prolong quality living.
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Recently, there has been an investment in the development of new, state-of the-art systems to 
better assess HRQOL for a variety of chronic health conditions. Specifically, the Quality of 
Life for Neurological Disorders (Neuro-QoL) measurement system [18, 19] and Patient-
Reported Outcomes Measurement Information System (PROMIS) [20] were designed to 
create and disseminate reliable and valid standardized PROs that measure key symptoms and 
health concepts. PROMIS was developed for use in individuals with chronic conditions, and 
Neuro-QoL extended this work to neurological disorders (stroke, PD, multiple sclerosis, 
child and adult epilepsy, amyotrophic lateral sclerosis, and muscular dystrophy). Neuro-QoL 
and PROMIS offer several advantages over more traditional measures. These systems allow 
for cross-disease comparison. In addition, PROMIS and Neuro-QoL contain many identical 
items that allow linkage between measures such that a score on one PROMIS measure can 
be used to estimate a score on a Neuro-QoL measure. Third, these PRO systems utilize 
computerized adaptive test (CAT) technology, a method whereby each individually 
administered item is selected based on the previous item response. CATs allow for the 
sensitive measurement of a broad range of symptomatology with the administration of a 
small subset of items (between 5 and 12 items) without losing the precision of a longer 
measure. This reduces response burden, which is particularly important in HD where motor, 
psychiatric, and cognitive symptoms may impair the ability to respond to long 
questionnaires. The exact subset of items administered in a CAT depends on upon item 
response theory (IRT) calibrations [21]. A calibrated item bank is a set of carefully crafted 
questions that develop, define, and quantify a common theme [22, 23]. The items can be 
arranged along a scale, e.g., from no symptoms to extreme symptoms. The dynamic nature 
of CAT allows for greater sensitivity across the disease spectrum than most traditional, static 
measures while still retaining the integrity of the full measure. This is especially relevant in 
HD, where many measures exhibit floor effects during the prodromal phase of the disease 
and ceiling effects for the later stages of the disease [24]. CAT also provides better precision 
and lower standard error than static measures, even when the number of items administered 
for each is identical [25]. This is true even when short forms target a specific end of a 
symptom trait (such as low-end or high-end fatigue) [25].
The purpose of the current study was to develop and validate a PRO measurement system 
that captures both the generic and more unique aspects of HRQOL in HD (‘‘HDQLIFE’’). 
Given the complexity of the multi-phase study to develop the HDQLIFE, this paper provides 
a broad introduction to the processes and aims of each phase of the study; further details on 
the methods and results of each phase are found in the companion articles [26–28]. Broadly, 
this study focused on validating existing measurement systems to capture generic, relevant 
aspects of HRQOL for individuals with HD (i.e., Neuro-QoL and PROMIS, described 
below), and developing additional content that would allow for disease-specific sensitivity 
utilizing a computer adaptive test framework (using PROMIS measurement development 
standards [29]). These results are complemented by the companion articles which include 
detailed presentations of exploratory and confirmatory factor analysis results, graded 
response model results, differential item functioning analysis results, as well as item-level 
calibration data and preliminary validation data generated using post hoc computer adaptive 
test simulations [26–28].
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Methods
Literature reviews and a qualitative focus group study [30] were conducted to characterize 
HD-relevant HRQOL domains (including the identification of relevant Neuro-QoL/PROMIS 
measures) and develop items for domains that were not captured within these existing 
systems. Next, a quantitative study served to: validate the existing, relevant Neuro-QoL/
PROMIS measures in individuals with HD, and create and validate new, HD-specific item 
banks (i.e., computer adaptive tests).
1. Item Development.
A qualitative focus group study and literature review were conducted to determine the 
domains, subdomains, and items that should be used to assess HRQOL in HD [30]. Focus 
groups were conducted with key HD stakeholders and included six groups with individuals 
at various stages of diagnosed, symptomatic HD, five groups with individuals either at risk 
for HD (i.e., have not been tested and were not diagnosed with HD yet but have a parent 
with HD) or with prodromal HD (i.e., have a positive gene test, but not diagnosed with 
manifest HD), three groups with non-clinical HD caregivers (e.g., family members), and two 
groups with HD clinicians (e.g., physicians, nurses). Participants discussed what the term 
‘‘quality of life’’ meant to them, what they believed to be the most important aspects of 
HRQOL, and how HD affected their HRQOL. Focus group discussions were transcribed 
verbatim and analyzed according to a well-established frequency analysis approach [31]. 
Detailed qualitative findings have been described elsewhere [30]. Briefly, results showed that 
several PROMIS/Neuro-QoL measures were relevant in HD and that a number of HD-
specific HRQOL issues were not captured by these PROs (see Fig. 1).
The next step of the development of the HDQLIFE measurement system was to create 
preliminary item pools examining chorea, speech and swallowing difficulties, and end of life 
issues. Each item pool went through several different iterations based on expert review, 
cognitive debriefing interviews with individuals with HD, literacy review, and translatability 
review (to enable future translation into different languages). Expert review included insight 
from measurement development experts and professionals with clinical expertise in HD; 
experts provided feedback with regard to item overlap, appropriateness of the content to 
each subdomain, wording suggestions/changes, and content coverage (i.e., that all aspects of 
the specified domain were represented). Additional items were developed in cases where 
content coverage was deemed inadequate. All new items were also reviewed by at least 5 
individuals with prodromal or symptomatic HD (i.e., cognitive debriefing) to ascertain 
comprehension, processes used to arrive at a particular response (retrieving relevant 
information from memory, response selection including motivation and social desirability), 
and overall relevance of an item to the content being measured [32]. All new items also 
underwent a literacy review using the Lexile framework [33] to ensure that the items were 
written no higher than a fifth-grade reading level. Thus, we maximized the accessibility of 
this measure to participants, regardless of their level of education or cognitive impairment. 
Finally, a translatability review was conducted to maximize the potential for this measure to 
be translated into other languages in the future. We focused on Spanish translation for this 
review. Forward and backwards Spanish translations were conducted by a Spanish-speaking 
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translation scientist to identify potential concerns, such as items that contained wording or 
concepts that would be difficult to translate.
HDQLIFE Chorea Item Pool—Literature review and focus group data were used to 
create an initial item pool of 141 chorea items; 75 items were deleted and 3 items were 
revised based on expert review, 0 items were deleted and 9 items were revised based on 
translation review, and 2 items were deleted and 5 items were revised based on cognitive 
interview feedback. The final chorea item pool was comprised of 64 items.
HDQLIFE Speech and Swallowing Item Pool—Literature review and focus group data 
were used to create an initial item pool of 102 speech and swallowing items; 49 items were 
deleted and 12 items were revised based on expert review, 1 item was deleted and 3 items 
were revised based on translation review, and 5 items were deleted and 25 items were 
revised based on cognitive interview feedback. The final speech and swallowing item pool 
was comprised of 47 items.
HDQLIFE End of Life Concerns Item Pool—Literature review and focus group data 
were used to create an initial item pool of 69 items related to end of life concerns; 21 items 
were deleted and 0 items were revised based on expert review, 0 items were deleted and 39 
items were revised based on translation review, and 3 items were deleted and 13 items were 
revised based on cognitive interview feedback. The final end of life concerns item pool was 
comprised of 45 items.
2. Quantitative Study.
Once the item pools were developed, all items were field tested in 536 individuals including 
those with prodromal HD and manifest HD to meet the standards established by PROMIS to 
develop new CATs [29].
Participants
Participants were 18 years old or older, able to read and understand English, had either a 
positive test for the HD gene mutation (CAG ≥ 36, but did not yet have an HD clinical 
diagnosis, n = 205) and/or a clinical diagnosis of HD (n = 331), and had the ability to 
provide informed consent. The Total Functional Capacity (TFC) [34], as determined by 
clinician-rated administration, was used to classify participants with an HD diagnosis as 
either early-stage (sum scores of 7–13) or later-stage HD (sum scores of 0–6; described in 
more detail, below). Participants were recruited at several locations in the USA to ensure a 
geographically diverse sample. This included eight established HD clinics (Los Angeles, 
CA; Iowa City, IA; Indianapolis, IN; Baltimore, MD; Ann Arbor, MI; Golden Valley, MN; 
St. Louis, MO; Piscataway, NJ), the National Research Roster for Huntington’s disease, 
online medical record data capture systems [35], and articles/advertisements in HD-specific 
newsletters and Websites. Participants were also recruited in conjunction with other ongoing 
research studies, such as Predict-HD (San Francisco, CA; Iowa City, IA; Indianapolis, IN; 
Baltimore, MD; St. Louis, MO; Cleveland, OH) [36–38], as well as in cooperation with HD 
support groups and HD specialized nursing home units (Phoenix, AZ; Tuscon, AZ; Denver, 
CO; Jacksonville, FL; Des Moines, IA; Louisville, KY; Lansing, MI; Robbins-dale, MN; 
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Lakewood, NJ; Plainfield, NJ; New York City, NY; Dallas, TX; Seattle, WA). Participants 
received monetary compensation ($40) for participating in this study.
Measures
Participants were evaluated using the Unified Huntington’s Disease Rating Scales (UHDRS) 
[39], a standardized clinical rating scale that assesses four components of HD: motor 
function, cognition, behavior, and functional abilities. Although the UHDRS has several 
documented shortcomings [24, 40–44], it is the most frequently used assessment measure in 
HD clinical trials [45] and is included in the common data element recommendations 
provided by the National Institute of Neurological Disorders and Stroke [46]. The reliability 
and internal consistency of the four components of the UHDRS have been well studied [39]. 
We examined Total Functional Capacity (TFC), Total Motor Score (TMS), Independence 
Scale, and two measures of Cognition (total score for Symbol Digit Modalities Test [SMDT] 
[47] and Stroop Interference [48, 49]). The TFC is a 5-item measure that provides an index 
of day-to-day functioning across the domains of occupation, finances, domestic chores, 
activities of daily living, and care level. Total score ranges from 0 to 13 with higher scores 
indicating better functioning. The TMS provides a composite measure of oculomotor 
function, dysarthria, chorea, dystonia, gait, and postural stability; higher scores indicate 
more motor dysfunction. The Independence Scale is rated from 0 to 100, with higher scores 
indicating better functioning/greater levels of independence. Executive function measures 
included the SDMT (processing speed) and Stroop tests (interference); higher scores 
indicate better performance. Participants also were administered the Problem Behaviors 
Assessment Scale (PBA-s) [50] which is a clinician-administered assessment of behavior. 
For the purposes of this study, we examined clinician-rated Apathy, Irritability, Aggression, 
Anxiety, and Depression.
Participants completed the three newly developed HDQLIFE item pools (n = 64 chorea 
items, n = 47 speech/swallowing difficulties items, and n = 45 end of life concerns items). 
Participants also completed CATs for 12 PRO item banks from the Neuro-QoL and PROMIS 
identified as relevant to HD (Anxiety, Anger, Stigma, Emotional and Behavioral Dyscontrol, 
Positive Affect and Well-Being, Depression, Ability to Participate in Social Roles and 
Activities, Satisfaction with Social Roles and Activities, Lower Extremity Function/
Mobility, Upper Extremity Function/ADLs, Applied Cognition Executive Functioning, and 
Applied Cognition General Concerns). Finally, participants completed two generic measures 
of HRQOL, the 12-Item World Health Organization Disability Assessment Schedule 2.0 
(WHODAS 2.0) [51] and the Euro-Qol-5D (EQ5D) [52]. The WHODAS 2.0 is a 12-item 
standardized self-report measure of functioning and disability; higher scores indicate worse 
HRQOL. The EQ5D is a 5-item standardized measure of health status; higher scores 
indicate worse overall HRQOL.
Missing Data
Missing data rates were generally very low. The majority of our sample (99 %) had complete 
data for clinician-rated motor, functioning, and behavioral assessments (i.e., PBA-s and 
UHDRS Motor, Independence, and TFC measures); 99 % completed the EQ5D; 93–96 % 
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completed the clinician-administered cognition measures (i.e., UHDRS SDMT and Stroop 
Interference); 93–95 % completed the HDQLIFE measures; 91–92 % completed the 
PROMIS/Neuro-QoL measures; and 89 % completed the WHODAS. Not surprisingly, rates 
of data loss were higher for the late-stage HD participants relative to both of the other HD 
groups for most of the measures (for prodromal vs. late-stage HD all X2 p < .05 except for 
HDQLIFE Speech Difficulties; for early vs. late-stage HD all X2 p < .05 except for the 
HDQLIFE measures and Neuro-QoL Positive Affect and Well-Being). IRT models (the 
primary method used in this paper) are designed to handle missing data; the less missing 
data, the more stable parameter estimation. In general, less than 50 % of missing data for 
IRT models is considered acceptable [53, 54].
Data Capture
Study participants generally completed all measures (clinician-administered and PROs) 
within a 2-week time frame. PROs were completed through Assessment Center (https://
www.assessmentcenter.net), either at a designated computer during the research visit (for 
individuals with restricted access to a computer or the internet), or on a personal or 
publically available computer with an Internet connection. Participants could opt to 
complete PROs independently, or with the assistance of local site staff or a family member; 
participants and caregivers were instructed that response selections should always be those 
of the participant. They were instructed that assistance should be limited to logging in to the 
online study, reading questions, and/or clicking response options, when appropriate; 
participants were provided the following written and verbal instructions, ‘‘IMPORTANT: It 
is okay if you ask a caregiver/friend/family member to help you complete this survey (use 
the mouse and keyboard or touchscreen), but we want to make sure that the answers reflect 
what you feel and believe. It is not okay for the caregiver/friend/family member to answer 
questions for you; each response should be based on what you believe and feel.’’ Upon 
survey completion, participants were also asked to indicate whether they received help 
completing the survey: 65 % indicated completing the assessments independently; 15 % 
indicated receiving assistance from a caregiver/family member/friend; 10 % indicated 
receiving assistance from study staff; these data were missing for 9 % of participants. 
Participants indicating that they received assistance were also asked to indicate the type of 
assistance they received (participants could indicate more than one response): 89 participants 
indicated needing help using the computer/ipad (i.e., using mouse and/or keyboard or 
touchscreen); 67 participants indicated that his/her caregiver (family member, or friend) 
helped explain questions; 34 participants indicated that their caregiver (family member, or 
friend) answered questions by reminding them of important information; and 17 participants 
indicated that a caregiver (family member, or friend) helped by answering questions.
Psychometric Analysis Steps
Development of the new HRQOL item banks and CATs involved identifying unidimensional 
sets of items and conducting item response theory (IRT) [55] analyses to develop the 
calibration data needed to program the CAT.
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Each item pool (i.e., chorea, speech and swallowing difficulties, and end of life issues) was 
analyzed separately using factor analyses implemented in MPLUS (version 6.12) [56]; the 
sample was randomly divided into two separate datasets for these analyses. In the first 
dataset, exploratory factor analysis (EFA) was used to establish the number of 
unidimensional factors within each item pool as determined by: eigenvalues >1; scree plot 
review (i.e., number of factors before the break in the scree plot); and number of factors that 
explained >5 % of the variance. A promax rotation then was used to examine the association 
among factors by calculating their loadings (criterion > 0.4) and inter-factor correlations. 
Each unidimensional set of items (determined by EFA) was then subjected to confirmatory 
factor analysis (CFA) to assess model fit using the second randomly generated dataset. An 
iterative process including clinical input was taken into account to finalize item exclusion/
inclusion [57–59].
Once unidimensional item sets were identified, an IRT graded response model (GRM) [60] 
was implemented in IRTPRO (version 2.1) [61]. To be retained, items had to demonstrate 
good psychometric properties. Items were also examined for differential item functioning 
(DIF) based on age, gender, and education; the LORDIF package within R (version 0.3–2) 
[62] was used to conduct these analyses [63]. DIF is an indication of unexpected behavior by 
an item on a test, such that an item performs differently for a subgroup of participants when 
it should not (e.g., men perform better than women). Items exhibiting DIF for age, gender, 
and/or education were excluded from the final item set.
Administration time for these new measures was recorded, and a univariate analysis was 
conducted to determine whether there were significant differences for the HD groups 
(prodromal vs. early-, vs. late-HD). An exploratory analysis examining Pearson correlations 
between CAG repeat number and the new HDQLIFE measures was also conducted.
Validation of PROMIS/Neuro-QoL
Pearson correlations between the PROMIS/Neuro-QoL measures and comparator measures 
were calculated to examine construct validity. Comparator measures included two generic 
self-report measures of HRQOL (WHODAS 2.0 [64] and EQ-5D [52]), as well as selected 
measures from two clinical rated measures: the UHDRS (TMS, Independence Scale, Symbol 
Digit Modalities Test [47], and Stroop Interference) [39] and the PBA-s (Apathy, Irritability, 
Aggression, Anxiety, and Depression) [50]. To demonstrate adequate construct validity, 
correlations between the new measures and generic measures should be moderate to large (r 
= 0.5–0.8) and correlations with clinician measures should be small to moderate (r = 0.2–
0.4) [65].
Sample Size Considerations
Sample size consideration was determined based on the need for IRT analysis, the primary 
method in the current effort. While sample sizes of 200–1000 have been proposed when 
using graded response model (GRM), in which a larger sample size can produce more stable 
parameter estimation [60, 66], rules of thumb dictate that a minimum of 5–10 individuals are 
needed for every item within an item pool [67–69]. With an average of 50 items per item 
pool, 500 individuals were needed for reliable item response theory (IRT) calibration data. 
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Additionally, differential item functioning (DIF) analyses (an indication of item bias) can be 
performed provided that there are at least 200 participants within each condition; sampling 
stratification considered age (B40 vs. [40 and B50 vs. [50), gender (male vs. female), and 
education (Bhigh school vs. [high school]) [70].
Results
Participant demographics
Five hundred thirty-six individuals with HD (prodromal and manifest) participated in this 
study (Table 1); 205 individuals had prodromal HD, 202 had early-stage HD, and 125 had 
late-stage HD (4 participants did not have enough information to designate a classification). 
There were no significant group differences for sex, X2(2, 532) = 4.29, p = .12, but there 
were small differences across groups for education; F(2, 506) = 16.18, p < 0.0001, with 
early-HD and late-HD groups having 1 to 1.5 fewer years of education than the prodromal 
HD group. As expected, since HD symptoms progress with age, analysis of age of the 
groups showed significant differences among the three groups, F(2, 529) = 45.01, p < .0001. 
The prodromal group (M = 45.65, SD = 11.99) was significantly younger than both manifest 
groups, and the early-HD group (M = 51.42, SD = 12.80) was significantly younger than the 
late-HD group (M = 42.56, SD = 12.08).
New HDQLIFE CAT Development
Across the 3 item pools, 156 items were field tested. For the chorea item pool, EFA and CFA 
supported 34 unidimensional items; the final Chorea item bank is comprised of 34 items 
(detailed analyses can be found in [27]). For the speech and swallowing difficulties item 
pool, EFA and CFA supported two separate unidimensional sets of items: difficulties with 
speech (27 unidimensional items) and difficulties with swallowing (15 unidimensional 
items). The final Speech Difficulties item bank is comprised of 27 items (no items were 
deleted based on IRT; detailed analyses can be found in [28]), and the final Swallowing 
Difficulties item bank is comprised of 16 items (1 item was deleted based on IRT; detailed 
analyses can be found in [28]). Finally, for the end of life item pool, EFA and CFA 
supported two unidimensional item sets: Concern with Death and Dying (12 unidimensional 
items) and Meaning and Purpose (7 items). The final Concern with Death and Dying item 
bank is comprised of 12 items (no items deleted based on IRT; detailed analyses can be 
found in [26]). There were not enough items retained to develop a CAT for Meaning and 
Purpose; thus, 4 items comprised the final Meaning and Purpose short form (3 items were 
deleted based on IRT; detailed analyses can be found in [26]). Four new CATs were 
developed: Chorea, Speech Difficulties, Swallowing Difficulties, and Concern with Death 
and Dying. Six-item short forms were selected by expert review for each of these measures; 
a 4-item short form was developed to assess Meaning and Purpose. The analysis results for 
the new HDQLIFE measures are shown in Table 2. Average administration time for each 
new HDQLIFE measure was less than 1 min; univariate analyses indicated significant 
differences among all three groups for all measures (in all cases, prodromal participants had 
the fastest completion times, early-HD completion times were in the middle, and late-HD 
participants had the slowest completion times; Table 3).
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All newly developed HDQLIFE measures are scored on a t metric with a mean of 50 and 
standard deviation of 10, which is the same metric utilized for Neuro-QoL/PROMIS [71]. 
Thus, scores below 40 (1.0 SD below the mean) can be considered low and scores above 60 
can be considered high. Note that the referent group (i.e., the group used to develop the 
algorithm for the CATs) for the new measures (i.e., Chorea, Speech Difficulties, Swallowing 
Difficulties, Concern with Death and Dying, and Meaning and Purpose) are individuals with 
HD, while the referent group for the Neuro-QoL/PROMIS measures is the general 
population. There were significant group differences among the three HD groups on all of 
the HDQLIFE measures except Concern with Death and Dying and Meaning and Purpose 
(Table 4); differences were in the expected direction. There were also statistically significant 
though very modest associations between CAG repeat number and all of the new HDQLIFE 
measures except Meaning and Purpose (r = .21, p < .01 for HDQLIFE Chorea; r = .20, p < .
01 for HDQLIFE Speech Difficulties; r = .23, p < .01 for HDQLIFE Swallowing 
Difficulties; r = .11, p < .05 for HDQLIFE Concern with Death and Dying; and r = −.07, p 
> .05 for HDQLIFE Meaning and Purpose) providing preliminary support for construct 
validity of these new measures.
Preliminary support for Neuro-QoL/PROMIS Validity—Descriptive information 
regarding the Neuro-QoL/PROMIS measures, other generic self-reported measures of 
HRQOL, and clinician-rated assessments is provided in Table 4; for most measures, 
prodromal HD performed better than early-HD and late-HD, and early-HD performed better 
than late-HD. Neuro-QoL/PROMIS had moderate to strong relationships with generic self-
report measures of HRQOL (r’s ranged from .34 to .74; Table 5). Neuro-QoL/PROMIS 
measures generally had moderate relationships with clinician-rated measures (r’s ranged 
from .35 to .70 with the majority between .42 and .49). Correlations tended to be highest 
between Neuro-QoL/PROMIS physical, social, and cognitive measures and corresponding 
self-report measures of these same constructs. Correlations were lowest among PROMIS 
emotion measures and corresponding measures, and highest among Neuro-QoL physical 
functioning measures and corresponding measures.
Discussion
Clinical trials aimed at slowing the progression of HD are underway. Unfortunately, these 
clinical studies employ few cross-disease comparison and may not be sufficiently sensitive 
to detect small but clinically meaningful changes in function [72]. Furthermore, existing 
PROs are often lengthy and time intensive. This is especially problematic given the 
regulatory and public interests to include PROs as meaningful endpoints in clinical trials 
[73]. The HDQLIFE measurement system uses state-of-the-art measurement techniques to 
help remedy these problems. HDQLIFE includes 12 validated Neuro-QoL/PROMIS 
measures in HD, as well as five new HD-specific measures: Chorea, Speech Difficulties, 
Swallowing Difficulties, Concern with Death and Dying, and Meaning and Purpose. 
HDQLIFE is unique in that it includes new HD-specific items based upon direct input from 
participants living with HD or the threat of HD, and consultation with experts who work 
with individuals with HD. HDQLIFE also includes ‘‘generic’’ items from PROMIS and 
Neuro-QoL to enable comparisons across different medical populations. Thus, HDQLIFE 
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allows for both HD specificity and cross-disease comparisons, providing a significant 
advantage to more traditional measurement systems that require a trade-off between these 
two functions.
The HDQLIFE is also the first PRO assessment in HD to utilize item banking and CAT 
methodology. In CAT, each individual item is selected based on the response to the previous 
item. This ‘‘smart test’’ allows clinicians and researchers to ascertain a person’s level of 
functioning using only a minimal number of items without losing the precision of a longer 
measure. CAT offers several advantages to traditional test administration, including 
specification of the minimum/maximum number of items, and/or maximum acceptable 
standard error. Further, most measures can be administered as fixed-length short forms (4–8 
items), effectively reducing test length without sacrificing test sensitivity (i.e., administration 
time for each new HDQLIFE measure was less than 1 min). This is particularly important 
given time constraints inherent in clinical trials assessment and the need to limit participant 
burden during test administration, which is especially important during later-stage HD when 
cognition is compromised and processing speed is slowed [12]. CAT also has the advantage 
that new items can be evaluated for consistency with the original bank and then added at a 
later date, allowing for future expansion and adjustment.
There are several limitations to this study. First, this study sample was comprised of 
participants who were recruited through other research studies and through large, established 
HD clinics; this convenience sample may not represent the HD population at large. 
Specifically, while there is no evidence to suggest that there are gender differences in HD in 
the general population [74], our sample included slightly more females (59 %) than males. 
While consistent with other research studies in HD (females comprise 55–64 % of other 
large HD cohorts [75, 76]), and in research studies more generally [77–79], it is possible that 
our findings are not fully representative of males with HD. With regard to education, our 
prodromal participants were more highly educated than the manifest participants. This is not 
surprising given that individuals with greater education also have greater medical genetic 
knowledge [80] and are more likely to get medical testing [81] and that individuals with 
higher education are more likely to participate in HD research studies [36, 37, 82]. Rates for 
race/ethnicity were consistent with established prevalence rates [83–86] and other large HD 
research cohorts [75, 76, 87]. Second, participants completed the survey in multiple ways 
(online during research visits, online at home, by phone interview, or by in-person interview) 
and assistance was provided when appropriate (e.g., help logging into the online survey, help 
clicking the responses). Since a portion of the surveys were completed at home, it is possible 
that some participant answers were influenced by a person providing assistance with the 
survey. In addition, a small percentage of participants indicated that their caregiver (family 
member, or friend) answered questions for them or answered questions by reminding them 
of important information. A recent high-quality meta-analysis indicates that mode of PRO 
administration, including completing on paper versus electronically or independently versus 
with help, does not cause bias [88]; however, future work is warranted to better understand 
how this may have influenced responding. Third, survey completion allowed multiple 
sittings, as long as it was generally completed within two weeks of the clinic visit when the 
UHDRS and PBA-s were administered. Since the survey was not always completed at the 
same time as the in-clinic assessments, it is possible that the correlations between these 
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measures were less robust than if they had been completed concurrently. Lastly, due to the 
effect of the disease on cognition, some of the HD participants, particularly those in the late 
stage of the disease, may not provide reliable self-reports of symptoms and concerns. 
Furthermore, we know that a small portion of our sample (largely our later-stage 
participants) were more likely to have incomplete survey data; some of this data loss was 
due to participant fatigue, while other data loss was due to practical limitations related to 
exceeding study visit lengths for reserved testing space (and an inability to complete the 
assessment outside of the clinic visit). Thus, additional work is needed to determine when 
self-report becomes unreliable [89].
The ultimate utility of the HDQLIFE will depend on its demonstration as a clinically 
meaningful outcome measure in controlled clinical trials of promising treatments for HD. 
Data from this study support the utility of the HDQLIFE as a standardized outcome 
instrument for efficiently capturing HRQOL in HD clinical and research settings. HDQLIFE 
will be available, free of charge, through www.assessmentcenter.net. Since HD is a relatively 
rare condition, the CAT platform of HDQLIFE should maximize the effectiveness of clinical 
trials by minimizing the number of participants needed to detect clinically meaningful 
changes in levels of function. The ability to conduct cross-disease comparisons may support 
advances in other neurodegenerative diseases. This should allow researchers to more 
effectively target interventions that are successful in diseases exhibiting symptom overlap 
with HD. The HDQLIFE offers a brief and more relevant alternative to current lengthier 
assessments of HRQOL. The HDQLIFE can also be used in the clinical setting, allowing 
patients to more effectively communicate symptoms of concern to treatment providers. This 
can also be accomplished from their home computers, tablets, and smart phones, facilitating 
better communication with HD specialists who may be geographically far from patients 
[90]. HDQLIFE provides the next generation of HRQOL measurement specific to HD, a 
disease that brings unique challenges and thus requires a validated assessment of the aspects 
of HRQOL that matter to HD patients and their caregivers.
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Fig. 1. 
Components of the HDQLIFE measurement system
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Table 1
Demographic data for the HDQLIFE participants
Variable Prodromal (n = 205) Early (n = 202) Late (n = 125) All (n = 536)
Age (years)*
 M (SD) 42.56 (12.08) 51.42 (12.80) 54.69 (11.99) 48.74 (13.31)
Sex
 Female 64.4 54.5 57.6 59.0
 Male 35.6 45.5 42.4 41.0
Ethnicity
 Not Hispanic or Latino 92.7 92.6 96.8 93.5
 Hispanic or Latino 1.5 4.5 0.8 2.4
 Not provided 5.9 3.0 2.4 4.1
Race (%)
 Caucasian 97.6 96.5 92.8 95.9
 African American 0.0 2.0 6.4 2.2
 Other 2.0 1.5 0.8 1.6
 Unknown 0.5 0.0 0.0 0.4
Education (years)*
 M (SD) 15.91 (2.94) 14.71 (2.78) 14.20 (2.60) 15.05 (2.88)
Marital status
 Single, never married 15.6 14.4 11.2 14.0
 Married 64.4 51.0 58.4 57.8
 Separated/divorced 13.2 23.8 22.4 19.2
 Widowed 0.0 3.0 3.2 1.9
 Living with partner 2.9 4.0 0.0 2.6
 Unknown 3.9 4.0 4.8 4.5
Years since diagnosis (n = 159) (n = 77) (n = 238)
 M (SD) – 3.07 (3.71) 5.88 (4.62) 3.97 (4.22)
CAG repeats (n = 195) (n = 154) (n = 61) (n = 412)
 M (SD) 42.19 (2.90) 43.19 (2.90) 43.19 (3.92) 42.90 (4.09)
Entries in the table represent percentage of participants unless otherwise specified
*
There were significant group differences for this variable
Qual Life Res. Author manuscript; available in PMC 2018 August 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Carlozzi et al. Page 21
Ta
bl
e 
2
N
ew
 H
D
QL
IF
E 
me
asu
res
 st
ati
sti
cs
D
om
ai
n
Fi
na
l i
te
m
s
It
em
s 
in
 
sh
or
t 
fo
rm
It
em
(s)
 re
m
o
v
ed
C
FI
 (>
.90
)
TL
I
R
M
SE
A
 (K
.15
)
C
hr
o
n
ba
ch
’s
 a
lp
ha
 (>
0.8
0)
It
em
-to
ta
l c
or
re
la
tio
n 
(>
0.4
0)
Sl
op
e r
an
ge
Th
re
sh
ol
d 
ra
ng
e
A
dm
in
ist
ra
tio
n 
tim
e 
(s)
 M
 
(S
D)
Ch
or
ea
34
6
0
0.
98
0.
98
0.
08
0.
98
A
ll 
> 
0.
4
2.
64
–6
.2
1
−
0.
39
 to
 2
.1
3
42
.4
3 
(31
.31
)
Sp
ee
ch
27
6
0
0.
98
0.
98
0.
09
0.
98
A
ll 
> 
0.
4
2.
91
–6
.3
2
−
0.
41
 to
 2
.4
2
41
.9
6 
(30
.85
)
Sw
al
lo
w
in
g
15
6
1
0.
99
0.
98
0.
12
0.
97
A
ll 
> 
0.
4
3.
06
–7
.1
1
0.
11
 to
 3
.0
0
43
.5
3 
(33
.36
)
D
ea
th
 a
nd
 D
yi
ng
12
6
3
0.
98
0.
96
0.
11
0.
94
A
ll 
> 
0.
4
1.
48
—
4.
57
−
0.
98
 to
 3
.6
5
45
.0
5 
(27
.32
)
M
ea
ni
ng
 a
nd
 P
ur
po
se
4
4
9
0.
99
0.
98
0.
11
0.
84
A
ll 
> 
0.
4
2.
26
–4
.7
5
−
3.
26
 to
 0
.1
1
35
.1
2 
(21
.07
)
CF
I C
on
fir
m
at
or
y 
Fi
t I
nd
ex
, 
TL
I T
u
ck
er
–
Le
w
is 
In
de
x
, 
RM
SE
A 
ro
o
t m
ea
n 
sq
ua
re
d 
er
ro
r
Qual Life Res. Author manuscript; available in PMC 2018 August 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Carlozzi et al. Page 22
Table 3
Administration times (seconds) for prodromal, early-, and late-stage HD participants
Prodromal HD M 
(SD)
Early-HD M (SD) Late-HD M (SD) F P Partial η2
HDQLIFE Chorea 20.80 (15.10) 50.37 (26.94) 67.94 (34.44) 138.67 <0.0001 0.36
HDQLIFE Speech Difficulties 22.33 (16.49) 46.67 (27.00) 68.70 (33.53) 126.18 <0.0001 0.34
HDQLIFE Swallowing Difficulties 21.86 (16.13) 49.98 (29.45) 71.97 (37.16) 128.19 <0.0001 0.34
HDQLIFE Concern with Death and Dying 30.64 (14.30) 48.53 (26.37) 63.84 (32.29) 70.62 <0.0001 0.22
HDQLIFE Meaning and Purpose 24.45 (14.44) 37.70 (18.56) 50.75 (24.67) 70.76 <0.0001 0.23
Significant differences were found between all groups
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Table 4
Average scores for clinician-rated and self-report assessments for prodromal, early-, and late-stage HD 
participants
Prodromal-HD Early-HD Late-HD All
Self-report measures HDQLIFE—M (SD)
 Speech Difficulties SFa,b,c 43.11 (6.66) 50.34 (7.50) 54.70 (7.70) 48.52 (8.50)
 Swallowing Difficulties SFa,b,c 50.16 (2.72) 53.83 (5.27) 57.31 (6.02) 53.18 (5.40)
 Chorea SFa,b,c 43.44 (3.80) 51.64 (7.79) 57.05 (8.20) 49.63 (8.52)
 Concern with Death and Dying SF 49.22 (8.31) 50.61 (8.63) 50.55 (10.62) 50.03 (9.00)
Meaning and Purpose SF 50.52 (9.06) 50.14 (9.62) 48.95 (8.26) 50.03 (9.12)
PROMIS—M (SD)
 Anger 46.16 (9.30) 47.95 (10.78) 47.26 (11.34) 47.17 (10.42)
 Anxiety 52.12 (8.20) 52.93 (9.91) 54.02 (10.11) 52.89 (9.40)
 Depressionb 47.70 (8.88) 50.2 (10.04) 51.9 (10.03) 49.73 (9.75)
Neuro-QoL—M (SD)
 Positive Affect and Well-Being 55.05 (7.05) 54.36 (8.50) 54.44 (7.75) 54.66 (7.76)
 Emotional Behavioral Dyscontrolb,c 44.41 (8.75) 47.59 (10.52) 47.56 (11.16) 46.30 (10.08)
 Physical Functioning—Upper Extremitya,b,c 51.64 (5.14) 44.32 (9.30) 32.14 (8.83) 44.73 (10.63)
 Physical Functioning—Lower Extremitya,b,c 55.81 (4.86) 48.04 (8.45) 39.01 (8.75) 49.27 (9.66)
 Applied Cognition—Executive Functioninga,b,c 47.41 (9.34) 39.43 (9.15) 27.13 (8.19) 40.09 (11.72)
 Applied Cognition—General Concernsa,b,c 45.21 (8.85) 40.00 (9.14) 35.59 (8.29) 41.14 (9.57)
 Stigmaa,b,c 43.43 (5.85) 50.15 (7.64) 52.34 (8.28) 47.93 (8.03)
 Ability to Participate with Social Roles and Activitiesa,b,c 52.31 (7.93) 48.44 (8.23) 42.94 (7.63) 48.87 (8.69)
 Satisfaction with Social Roles and Activitiesa,b 50.26 (6.51) 47.38 (6.18) 45.47 (6.74) 48.14 (6.68)
Generic HRQOL—M (SD)
 WHODASa,b,c 3.74 (5.31) 9.43 (8.59) 19.84 (11.20) 9.14 (9.95)
 EQ5D Health Scalea,b,c 84.30 (11.21) 78.45 (14.68) 73.35 (23.63) 79.50 (16.69)
 EQ5D Index Valuea,b,c .89 (.12) .80 (.14) .71 (.17) .81 (.15)
Clinician-rated measures
Motor and Independence—M (SD)
 UHDRS Total Motor Scorea,b,c 5.74 (6.28) 30.70 (14.68) 54.33 (21.28) 26.41 (23.49)
 UHDRS Independence Scalea,b,c 97.71 (5.95) 85.02 (9.65) 61.40 (12.13) 84.30 (16.62)
Emotional functioning (% impaired)
 PBA-s Anger/Aggression 33.8 41.3 33.6 36.6
 PBA-s Anxietya,c 51.5 65.0 50.0 56.3
 PBA-s Apathya,b 29.4 51.1 54.6 43.2
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Prodromal-HD Early-HD Late-HD All
 PBA-s Depressiona,c 42.7 61.0 45.1 50.2
 PBA-s Irritabilitya,c 49.0 61.0 43.4 52.3
Cognition M (SD)
 SDMT Raw Scorea,b,c 52.14 (10.93) 32.14 (11.59) 18.76 (10.10) 37.83 (16.93)
 Stroop Interference Number Correcta,b,c 46.37 (15.22) 28.92 (10.00) 18.30 (8.95) 33.75 (16.43)
WHODAS World Health Organization Disability Assessment Schedule 2.0, EQ-5D Euro-Qol-5D, UHDRS Unified Huntington’s Disease Rating 
Scales, PBA-s Problem Behaviors Assessment Scale, SDMT Symbol Digit Modalities Test, SF Short form, HRQOL Health-related quality of life, 
PROMIS Patient Reported Outcome Measurement Information System. HDQLIFE, PROMIS and Neuro-QoL scores are reported as t scores, all 
other scores reported are raw scores, except where noted
aUnivariate analyses indicated significant group differences between prodromal and early-HD
bUnivariate analyses indicates significant group differences between prodromal and late-HD
cUnivariate analyses indicates significant group differences between early- and late-HD
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